Metraipolis › archive › dc_25899877be33

Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study — Europe PMC PMID:41566486

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41566486
DOI
10.1186/s13223-[numero omesso]-9
License (as archived)
solo-consultazione
Archived
2026-10-07T22:04:13.609Z
SHA-256 of the archived text
59307b701ad3c48779fa72a65b543b3a18477c7e213f1644d06e52555a0a9d68
Stable URL of this page
https://metraipolis.com/documento/dc_25899877be33

How to cite

Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study — Europe PMC PMID:41566486 — Europe PMC (en), https://europepmc.org/article/MED/41566486 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_25899877be33 (Metraipolis archive dc_25899877be33, sha256 59307b701ad3c48779fa72a65b543b3a18477c7e213f1644d06e52555a0a9d68)
BibTeX
@misc{dc25899877be33,
  title = {Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study — Europe PMC PMID:41566486},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41566486},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_25899877be33; sha256 59307b701ad3c48779fa72a65b543b3a18477c7e213f1644d06e52555a0a9d68},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41566486. Agents can read the archived copy with the MCP tool read_document.